Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses

Simerska, Pavla, Suksamran, Tittaya, Ziora, Zyta Maria, Rivera, Fabian de Labastida, Engwerda, Christian and Toth, Istvan (2014) Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses. Vaccine, 32 37: 4743-4750. doi:10.1016/j.vaccine.2014.06.049


Author Simerska, Pavla
Suksamran, Tittaya
Ziora, Zyta Maria
Rivera, Fabian de Labastida
Engwerda, Christian
Toth, Istvan
Title Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses
Formatted title
Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-410X
1873-2518
Publication date 2014-01-01
Year available 2014
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2014.06.049
Open Access Status Not yet assessed
Volume 32
Issue 37
Start page 4743
End page 4750
Total pages 8
Place of publication London, United Kingdom
Publisher Elsevier
Language eng
Subject 2400 Immunology and Microbiology
2725 Infectious Diseases
2739 Public Health, Environmental and Occupational Health
3400 Veterinary
1313 Molecular Medicine
2700 Medicine
Abstract The lipid core peptide (LCP) system has successfully been used in development of peptide-based vaccines against cancer and infectious diseases (such as group A streptococcal infection). CD8 T cells are important targets for vaccines, however developing a vaccine that activates long-lasting immunity has proven challenging. The ability of LCP vaccines to activate antigen-specific CD8 and/or CD4 T cell responses was tested using compounds that contained two or four copies of OVA and/or OVA peptides conjugated to LCP, which are recognised by OTI (CD8 specific) and OTII (CD4 specific) T cells, respectively. The LCP-ovalbumin vaccines developed in this study were synthesised in 30% yields and showed no significant haemolytic effect on red blood cells (below 4% haemolysis when tested with compounds at up to 100μM concentrations). Promising in vivo data in mice suggested that this LCP-ovalbumin vaccine system could act as a novel and potent vehicle for the stimulation of robust antigen-specific CD8 T cell responses.
Formatted abstract
The lipid core peptide (LCP) system has successfully been used in development of peptide-based vaccines against cancer and infectious diseases (such as group A streptococcal infection). CD8 + T cells are important targets for vaccines, however developing a vaccine that activates long-lasting immunity has proven challenging. The ability of LCP vaccines to activate antigen-specific CD8 + and/or CD4 + T cell responses was tested using compounds that contained two or four copies of OVA 257–264 and/or OVA 323–339 peptides conjugated to LCP, which are recognised by OTI (CD8 + specific) and OTII (CD4 + specific) T cells, respectively. The LCP–ovalbumin vaccines developed in this study were synthesised in 30% yields and showed no significant haemolytic effect on red blood cells (below 4% haemolysis when tested with compounds at up to 100 μM concentrations). Promising in vivo data in mice suggested that this LCP–ovalbumin vaccine system could act as a novel and potent vehicle for the stimulation of robust antigen-specific CD8 + T cell responses.
Keyword Ovalbumin
Peptide synthesis
Vaccine development
Q-Index Code C1
Q-Index Status Confirmed Code
Grant ID DP1092829
Institutional Status UQ
Additional Notes Published online ahead of print 23 June 2014

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Chemistry and Molecular Biosciences
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 04 Jul 2014, 19:53:16 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences